2021
DOI: 10.1093/neuonc/noab196.038
|View full text |Cite
|
Sign up to set email alerts
|

Biom-07. Quantitative MGMT Promoter Methylation Index Indicates a Non-Linear Prognostic Effect in Glioblastoma, Suggesting That Use of Optimal Cutoff Points May Be Clinically Disadvantageous

Abstract: BACKGROUND Epigenetic inhibition of the O6-methylguanine-DNA-methyltransferase (MGMT) gene has emerged as a clinically relevant prognostic marker in glioblastoma (GBM). Methylation of the MGMT promoter has been shown to increase chemotherapy efficacy. While traditionally reported as a binary marker, recent methodological advancements have led to quantitative approaches that measure methylation, providing clearer insights into methylation’s functional relationship with survival. … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles